PharmaCyte Biotech (PMCB) Other Non Operating Income (2011 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Other Non Operating Income of $3.6 million for Q2 2026, up 75.42% year-over-year from $2.0 million in Q2 2025, and up 89.31% quarter-over-quarter from $1.9 million in Q1 2026.
PharmaCyte Biotech (PMCB) Other Non Operating Income (2011 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Other Non Operating Income for 15 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non Operating Income rose 75.42% year-over-year to $3.6 million; the TTM figure through Apr 2026 stood at -$4.7 million (down 145.43% YoY), while the FY2026 annual figure was -$4.7 million, down 145.43% from the prior year.
- Other Non Operating Income rose to $3.6 million in Q2 2026 per PMCB's latest filing, from $1.9 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $4.5 million in Q1 2025 and bottomed at -$10.5 million in Q4 2025.
- Historically, Other Non Operating Income has averaged $513481.3 across 5 years, with a median of $197979.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 385260.68% in 2023 and fell as far as 37073.58% in 2023.
- PharmaCyte Biotech's Other Non Operating Income stood at -$1058.0 in 2022, then surged by 385260.68% to $4.1 million in 2023, then sank by 55.12% to $1.8 million in 2024, then plunged by 672.66% to -$10.5 million in 2025, then jumped by 134.27% to $3.6 million in 2026.
- Business Quant data shows PMCB's Other Non Operating Income at $3.6 million in Q2 2026, $1.9 million in Q1 2026, and -$10.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 3.59 Mn |
| Jan 31, 2026 | 1.90 Mn |
| Oct 31, 2025 | -10.47 Mn |
| Jul 31, 2025 | 243,000.00 |
| Apr 30, 2025 | 2.05 Mn |
| Jan 31, 2025 | 4.49 Mn |
| Oct 31, 2024 | 1.83 Mn |
| Jul 31, 2024 | 2.08 Mn |
| Apr 30, 2024 | 710,000.00 |
| Jan 31, 2024 | 10,000.00 |
| Oct 31, 2023 | 4.08 Mn |
| Jul 31, 2023 | -1.45 Mn |
| Apr 30, 2023 | 54,008.00 |
| Jan 31, 2023 | 152,958.00 |
| Oct 31, 2022 | -1,058.00 |
| Jul 31, 2022 | -3,906.00 |
| Apr 30, 2022 | -1,573.00 |
| Jan 31, 2022 | -630.00 |
| Oct 31, 2021 | 25,097.00 |
| Jul 31, 2021 | -2,067.00 |